Imipenem | Community Health

Imipenem, sold under the brand name Primaxin, is a synthetic β-lactam antibiotic belonging to the carbapenems chemical class, developed by [[merck|Merck]] scientists [[burton-christensen|Burton Christensen]], [[william-leanza|William Leanza]], and [[kenneth-wildonger|Kenneth Wildonger]] in the mid-1970s. With its broad spectrum of activity against aerobic and anaerobic, Gram-positive and Gram-negative bacteria, imipenem has become a crucial treatment option for infections not readily treated with other antibiotics. Since its approval for medical use in 1985, imipenem has been administered through intravenous injection, providing a highly effective solution against multiple drug-resistant bacteria. The development of imipenem was a significant breakthrough, as it was created through a lengthy trial-and-error search for a more stable version of the natural product [[thienamycin|thienamycin]], which is produced by the bacterium [[streptomyces-cattleya|Streptomyces cattleya]]. Imipenem's impact on the medical field has been substantial, with over 10 million patients treated worldwide, and its sales have exceeded $1 billion annually. As a testament to its importance, imipenem has been included in the [[world-health-organization|World Health Organization's]] list of essential medicines, highlighting its critical role in global healthcare. With the rise of antibiotic resistance, imipenem remains a vital component in the fight against infectious diseases, and its discovery has paved the way for further research into carbapenem antibiotics.